MAESTRO Phase 3 NASH Clinical Trials of Resmetirom:
Optimal Strategies for the Identification of NASH Patients with Significant Liver Fibrosis

(as presented at AACE 2021)

Click icon in video above (bottom right) for full-screen

Collaboration Center